A Clinical Trial Evaluating the Safety Tolerability, Radiation Absorption Dose, Distribution, PET Imaging and Histological Expression of 68Ga-NOTA-SCH001 in Patients With Multiple Myeloma

Inclusion Criteria:

* 1\. The subjects sign the informed consent voluntarily and can complete the test according to the protocol requirements;

  2\. Over 18 years old, male or female;

  3\. Patients diagnosed with multiple myeloma;

  4\. ECOG score is 0-1; The expected survival time is not less than 3 months;

  5\. Women of childbearing age need to undergo urine pregnancy test, and enrolled patients must be negative for pregnancy test;

  6\. For fertile female patients or male patients with fertile partners, agree to remain abstinent during the study period (no

Or use one or more contraceptive methods with a failure rate of less than 1% per year for at least one year after the end of the study.

7\. CD38 monoclonal antibody therapy was not used before enrollment in this study.

Exclusion Criteria:

* General situation

  * Those who are unable to perform visits, or receive relevant tests, or treatment in accordance with the clinical trial protocol;
  * Can not tolerate venous puncture blood collection;
  * Patients with serious diseases or other malignant tumors, except those that the researchers determined to be in stable control;
  * Known severe allergy to SCH001, similar drugs or excipients;

Laboratory examination

• Serum virology test: any of the results of hepatitis B virus surface antigen, hepatitis C virus antibodies, syphilis specific antibodies

Positive or HIV-negative antibodies cannot be determined;

• Fasting blood glucose \>11.1mmol/L;

other

* No active infection
* Drug/alcohol abuse, severe mental disorders;
* Patients with claustrophobia, emotional instability, acute persistent spasms, or inability to keep their arms up and lie flat for 30 minutes;

Participants in any other clinical trial within 3 months prior to screening;

* Women who are pregnant or breastfeeding;
* The investigator did not consider it appropriate to participate in this clinical study.